期刊
PHARMACOGENOMICS
卷 17, 期 8, 页码 891-906出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2015-0016
关键词
breast milk; CYP2B6; infant exposure; nevirapine; pharmacokinetics
资金
- Tertiary Education Trust Fund of Nigeria at the University of Liverpool, UK
- Medical Research Council [G0800247] Funding Source: researchfish
- MRC [G0800247] Funding Source: UKRI
Aim: The influence of genetic factors on nevirapine (NVP) breast milk pharmacokinetics and breastfed infants' exposure were investigated. Patients & methods: Associations between nine SNPs in NVP disposition genes in mothers and its plasma and breast milk concentrations were explored in nursing mother-infant pairs. Results: NVP pharmacokinetics in maternal plasma, breast milk and infant exposure indices were influenced by CYP2B6 516G>T and 983T>C. The median (range) milk-to-plasma area under the curve (AUC(0-12)) ratio was 0.95 (0.56-1.5). Calculated as percentages of pediatric treatment, infant postexposure prophylaxis and maternal weight-adjusted doses, the maximum exposure indices were 3.64% (1.99-9.88), 26.0% (9.93-79.1) and 13.8% (5.77-27.7), respectively. Infant plasma concentration as a result of exposure through breast milk (n = 93), pre-exposure prophylaxis (n = 10) and both (n = 27) were 660 (104-3090), 1020 (401-3325) and 2720 ng/ml (1360-7290), respectively. Conclusion: The clinical significance of the observed differences between routes of infants' exposure warrants further investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据